Rise And Fall: PDUFA Fees Go Up But Some GDUFA Levies Come Down In FY 2015
NDA/BLAs with clinical data will cost 7.7% more starting Oct. 1, bringing the application fee to $2.34 million.
You may also be interested in...
FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.
Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.
Proportion of subjects with freedom from exogenous insulin ‘might support the efficacy’ of the allogeneic islet cellular therapy, US FDA says after concluding that issues in two studies limit interpretability of primary analyses based on severe hypoglycemic events and HbA1c levels. An advisory committee will weigh clinical efficacy, safety and product characterization issues.